# To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

> **NCT04593758** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cornerstone Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Sarcoma, Clear Cell

## Interventions

- **DRUG:** CPI-613 + Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04593758
- **Lead sponsor:** Cornerstone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2023-03-09
- **Final completion:** 2023-03-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04593758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04593758, "To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04593758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*